From the source
OpenAI has acquired Orchestra Bio, a startup whose platform coordinates drug development work across biopharma teams, and is folding its team and technology into Rosalind, OpenAI's life sciences brand.
- OpenAI says the goal is to help scientists manage the work that turns discoveries into treatments, noting that developing a new medicine takes roughly 10 to 15 years on average from target discovery through US regulatory approval.
- Orchestra Bio built its platform around people and AI agents working together: scientists hand off monitoring and tracking of studies to agents, which pinpoint the activities and timelines a problem touches and compare response options.
- Orchestra Bio, which started four years earlier, said it is joining OpenAI "to continue our mission at an even greater scale."
- Rosalind Workbench is in research preview, with an Explore mode using the latest ChatGPT models and a Research mode applying GPT-Rosalind to complex biological questions through an application process.
- OpenAI's product page reports benchmark results for GPT-Rosalind stated as increases in performance per token: 53.7% on Genebench, 18.0% on Medchem Bench, 19.6% on Labworkbench, and 4.42% on LifeSci Bench.